What is Lumen Bioscience?
Lumen Bioscience is pioneering a transformative approach to biopharmaceutical development by leveraging a unique spirulina-based platform. This innovative system is designed to enhance the speed and reduce the cost of producing biologics, offering a significant departure from traditional methods. The company's technology facilitates straightforward assembly of complex therapeutic cocktails and enables mass-market scale production. Lumen's pipeline includes investigational oral biologic drugs and dietary supplements aimed at conditions such as weight loss, C. difficile infection, inflammatory bowel disease, kidney stone disease, and traveler's diarrhea, all of which have historically been challenging to address with conventional biopharmaceutical tools.
How much funding has Lumen Bioscience raised?
Lumen Bioscience has raised a total of $59.4M across 4 funding rounds:
Series A
$13M
Debt
$350K
Series B
$16M
Series C
$30M
Series A (2017): $13M with participation from BioEconomy Capital, U.S. Department of Energy, and Avista Development
Debt (2020): $350K led by PPP
Series B (2020): $16M supported by WestRiver Management, Columbia Pacific, Avista Development, and Bioeconomy Capital
Series C (2025): $30M featuring Bill & Melinda Gates Foundation and WestRiver Group
Key Investors in Lumen Bioscience
U.S. Department of Energy
The U.S. Department of Energy is a federal agency responsible for energy policy and national security, managing the nation's nuclear weapons complex and driving innovation in energy conservation and fundamental research. It also oversees radioactive waste management and nuclear propulsion systems for naval vessels.
Avista Development
Avista Development, part of Avista Corporation, is an energy utility company involved in electric and natural gas services, sheet metal fabrication, commercial real estate, and emerging technology venture capital. They focus on renewable energy sources and comprehensive service infrastructure.
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation is dedicated to supporting individuals facing extreme poverty and hunger, aiming to help people lead healthier lives through its global initiatives and funding.
What's next for Lumen Bioscience?
With its recent strategic investment and substantial total funding, Lumen Bioscience is well-positioned for its next phase of growth. The company's focus on developing biologics that act locally in the gut, coupled with its cost-effective and scalable manufacturing platform, suggests a strategic move towards making advanced therapies more accessible. Future developments will likely center on advancing its investigational drugs through clinical trials and expanding its manufacturing capabilities to meet anticipated market demand. The company's ability to address a range of high-prevalence conditions indicates a broad market opportunity and a potential to disrupt multiple therapeutic areas within the biopharmaceutical industry.
See full Lumen Bioscience company page
